Adaptimmune Therapeutics (NASDAQ:ADAP) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research note published on Sunday. The brokerage issued a buy rating on the biotechnology company’s stock.

Several other brokerages have also recently weighed in on ADAP. HC Wainwright reduced their price target on Adaptimmune Therapeutics from $3.50 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Scotiabank reduced their target price on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a report on Friday, March 21st. Wells Fargo & Company lowered their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a report on Friday, March 21st. Finally, Guggenheim reduced their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating for the company in a research note on Wednesday, March 26th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1.83.

Adaptimmune Therapeutics Stock Down 12.0 %

Shares of NASDAQ ADAP opened at $0.23 on Friday. The business’s fifty day moving average price is $0.45 and its 200-day moving average price is $0.62. Adaptimmune Therapeutics has a one year low of $0.20 and a one year high of $1.48. The stock has a market capitalization of $58.03 million, a PE ratio of -1.03 and a beta of 2.84. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). The business had revenue of $3.22 million for the quarter, compared to the consensus estimate of $16.56 million. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. On average, equities research analysts anticipate that Adaptimmune Therapeutics will post -0.14 EPS for the current year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ADAP. Jane Street Group LLC lifted its holdings in shares of Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 98,581 shares during the last quarter. Virtu Financial LLC increased its position in shares of Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 21,769 shares during the last quarter. FMR LLC lifted its position in Adaptimmune Therapeutics by 3.0% in the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock worth $1,655,000 after buying an additional 50,419 shares during the last quarter. Two Sigma Advisers LP boosted its stake in Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock worth $38,000 after buying an additional 58,787 shares in the last quarter. Finally, Two Seas Capital LP bought a new position in Adaptimmune Therapeutics during the fourth quarter valued at approximately $7,992,000. 31.37% of the stock is owned by hedge funds and other institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.